Recent Company News

• 03:07 AM ET Jul 02, 2025
  

  UCB upgraded to buy from neutral at BofA (pre-open) (€166.85, 0.00)

• 04:07 AM ET Jun 23, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:52 AM ET Jun 27, 2025
  

  StreetAccount Summary - European pre-market trading update

• 01:10 AM ET Jun 27, 2025
  

  UCB's GEMZ phase 3 study of fenfluramine in CDKL5 Deficiency Disorder shows positive results (€168.80, 0.00)

• 05:05 PM ET Jun 23, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 09:03 AM ET Jun 23, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:51 AM ET Jun 23, 2025
  

  Energy, tech and construction the best performers; chemicals biggest laggard:

• 01:43 AM ET Jun 23, 2025
  

  UCB upgraded to overweight from equal-weight at Morgan Stanley (€157.50, 0.00)

• 07:05 AM ET Jun 20, 2025
  

  UCB to presnt latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference (€158.45, +0.80)